e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
Tsai T-H., Su K-Y., Wu S-G., Chang Y-L., Luo S-C., Jan I-S., Yu C-J., Yu S-L., Shih J-Y., Yang P-C.
Source:
Eur Respir J 2012; 39: 677-684
Journal Issue:
March
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tsai T-H., Su K-Y., Wu S-G., Chang Y-L., Luo S-C., Jan I-S., Yu C-J., Yu S-L., Shih J-Y., Yang P-C.. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012; 39: 677-684
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Source: Eur Respir J 2013; 41: 417-424
Year: 2013
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
Source: Eur Respir J 2008; 32: 924-930
Year: 2008
Survival of lung adenocarcinoma patients with malignant pleural effusion
Source: Eur Respir J 2013; 41: 1409-1418
Year: 2013
Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer
Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema
Year: 2020
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma
Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Year: 2006
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
Source: Eur Respir J 2011; 38: 903-910
Year: 2011
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
Tumor-derived tumor necrosis factor-α promotes Lewis lung cancer-induced malignant pleural effusions in mice
Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer
Year: 2006
Diagnostic significance of ADAM8 in non-small cell lung cancer and malignant pleural effusion
Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology
Year: 2008
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
Source: ERJ Open Res, 7 (1) 00787-2020; 10.1183/23120541.00787-2020
Year: 2021
The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Sensitivity of PD-L1 analysis from pleural effusion in non-small cell lung cancer
Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Year: 2020
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
Management of EGFR mutated nonsmall cell lung carcinoma patients
Source: Eur Respir J 2015; 45: 1132-1141
Year: 2015
The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020
Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer
Source: Annual Congress 2005 - What's new in the pleura
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept